IL129149A - beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE - Google Patents

beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE

Info

Publication number
IL129149A
IL129149A IL12914997A IL12914997A IL129149A IL 129149 A IL129149 A IL 129149A IL 12914997 A IL12914997 A IL 12914997A IL 12914997 A IL12914997 A IL 12914997A IL 129149 A IL129149 A IL 129149A
Authority
IL
Israel
Prior art keywords
beta
compositions containing
matrix metalloproteinase
hydroxamic acids
tace inhibitors
Prior art date
Application number
IL12914997A
Other languages
English (en)
Other versions
IL129149A0 (en
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Publication of IL129149A0 publication Critical patent/IL129149A0/xx
Publication of IL129149A publication Critical patent/IL129149A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
IL12914997A 1996-10-16 1997-10-08 beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE IL129149A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72935996A 1996-10-16 1996-10-16
PCT/US1997/018170 WO1998016506A1 (en) 1996-10-16 1997-10-08 Beta-sulfonamido hydroxamic acids as matrix metalloproteinase and tace inhibitors

Publications (2)

Publication Number Publication Date
IL129149A0 IL129149A0 (en) 2000-02-17
IL129149A true IL129149A (en) 2003-10-31

Family

ID=24930685

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12914997A IL129149A (en) 1996-10-16 1997-10-08 beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE

Country Status (18)

Country Link
EP (1) EP0934259B1 (da)
JP (1) JP2001502326A (da)
KR (1) KR20000049198A (da)
CN (1) CN1105101C (da)
AR (1) AR008676A1 (da)
AT (1) ATE224364T1 (da)
AU (1) AU736134B2 (da)
BR (1) BR9712524A (da)
CA (1) CA2268895A1 (da)
DE (1) DE69715647T2 (da)
DK (1) DK0934259T3 (da)
ES (1) ES2184069T3 (da)
HK (1) HK1020720A1 (da)
IL (1) IL129149A (da)
NZ (1) NZ335053A (da)
PT (1) PT934259E (da)
WO (1) WO1998016506A1 (da)
ZA (1) ZA979236B (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT952148E (pt) * 1998-04-10 2004-09-30 Pfizer Prod Inc Derivados de acido ciclobutil-ariloxiarilsulfonilamino-hidroxamico
EP1087937A1 (en) 1998-06-17 2001-04-04 Du Pont Pharmaceuticals Company Cyclic hydroxamic acids as metalloproteinase inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
BR0007784A (pt) 1999-01-27 2002-02-05 American Cyanamid Co Composto, método para inibir mudanças patológicas mediadas pela enzima que converte o tnf-alfa (tace) em um mamìfero, composição farmacêutica, e, processo para preparar um composto
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
WO2000046189A1 (fr) * 1999-02-02 2000-08-10 Shionogi & Co., Ltd. Derives de la sulfonamide a structures cycliques
KR100780989B1 (ko) * 2000-05-23 2007-11-29 오스모닉스 인코포레이티드 개질된 술폰아미드 중합체
JP2005507937A (ja) 2001-11-01 2005-03-24 ワイス・ホールディングズ・コーポレイション マトリックスメタロプロテイナーゼおよびｔａｃｅ阻害剤としてのアレンアリールスルホンアミドヒドロキサム酸
US7491718B2 (en) 2002-10-08 2009-02-17 Abbott Laboratories Sulfonamides having antiangiogenic and anticancer activity
US20040157836A1 (en) * 2002-10-08 2004-08-12 Comess Kenneth M. Sulfonamides having antiangiogenic and anticancer activity
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
ATE449760T1 (de) 2004-03-22 2009-12-15 Southern Res Inst Nichtpeptidinhibitoren von matrixmetalloproteinasen
FR2947268B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
FR2947270B1 (fr) 2009-06-30 2011-08-26 Galderma Res & Dev Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique
US20140275108A1 (en) 2013-03-15 2014-09-18 Galderma Research & Development Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics
IL237852A0 (en) 2015-03-19 2016-03-24 Yeda Res & Dev Antibodies against amphigoline, medical preparations containing them and their use
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
EP3199534B1 (en) 2016-02-01 2018-09-05 Galderma Research & Development Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics
BR112021006407A8 (pt) 2018-10-04 2022-12-06 Inst Nat Sante Rech Med uso de inibidores do egfr para ceratodermas

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
WO1994022309A1 (en) * 1993-04-07 1994-10-13 Glycomed Incorporated Synthetic matrix metalloprotease inhibitors and uses thereof
US5672598A (en) * 1995-03-21 1997-09-30 The Procter & Gamble Company Lactam-containing hydroxamic acids

Also Published As

Publication number Publication date
ATE224364T1 (de) 2002-10-15
EP0934259B1 (en) 2002-09-18
WO1998016506A1 (en) 1998-04-23
ZA979236B (en) 1999-07-15
CN1105101C (zh) 2003-04-09
AU736134B2 (en) 2001-07-26
IL129149A0 (en) 2000-02-17
KR20000049198A (ko) 2000-07-25
NZ335053A (en) 2000-10-27
DE69715647D1 (en) 2002-10-24
DE69715647T2 (de) 2003-02-20
DK0934259T3 (da) 2003-01-27
ES2184069T3 (es) 2003-04-01
JP2001502326A (ja) 2001-02-20
CN1240424A (zh) 2000-01-05
AU4979097A (en) 1998-05-11
BR9712524A (pt) 1999-10-19
EP0934259A1 (en) 1999-08-11
PT934259E (pt) 2003-01-31
AR008676A1 (es) 2000-02-09
CA2268895A1 (en) 1998-04-23
HK1020720A1 (en) 2000-05-19

Similar Documents

Publication Publication Date Title
IL129149A (en) beta-SULFONAMIDO HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASE AND TACE INHIBITORS, COMPOSITIONS CONTAINING THEM AND THEIR USE
ZA979238B (en) The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors.
HUP0000641A3 (en) Ortho-sulfonamido aryl hydroxamic acid derivatives, their use, as matrix metalloproteinase and tace inhibitors and pharmaceutical compositions containing them
IL138028A0 (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical use
NZ304689A (en) Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors
ZA979235B (en) The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors
IL136300A0 (en) Hydroxamic acid derivatives as matrix metalloprotease (mmp) inhibitors
AU7294098A (en) Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
HUP0101613A3 (en) Metalloprotease inhibitor (4-arylsulfonylamino)-tetrahydropyran-4-carboxylic acid hydroxamides and medicaments containing the same
ZA977700B (en) Phosphinic acid amides as matrix metalloprotease inhibitors.
NO972307D0 (no) Matriksmetallproteaseinhibitorer
HUP0000145A2 (en) Betha-sulfonyl hydroxamic acid derivatives with matrix maetalloproteinases inhibitor activity, use thereof and pharmaceutical compositions containing them
ZA974542B (en) New amino acid derivatives and their use as thrombin inhibitors.
ZA981532B (en) Reverse hydroxamate derivatives as matrix metalloprotease inhibitors, metalloprotease inhibitors, and TNF alpha inhibitors.
GB9401129D0 (en) Hydroxamic acid derivatives as metalloproteinase inhibitors
HUP9900390A3 (en) Serine protease inhibitors, and pharmaceutical compositions containing them
IL127262A0 (en) Matrix metalloproteinase inhibitors
HUP9904165A3 (en) 3-mercaptoacetylamino-1,5-substituted-2-oxo-azepan derivatives useful as inhibitors of matrix metalloproteinase and use thereof
HRP970245B1 (en) Biaryl acetilenes as matrix metalloprotease inhibitors
HUP0100564A3 (en) Matrix metalloproteinase inhibitors and pharmaceuticals comprising them
AU7066398A (en) Novel use of matrix metalloproteinase inhibitors
AU1836800A (en) Amidomalonamides and their use as inhibitors of matrix metalloproteinase
ZA964668B (en) Hydroxamic acid and amino-carboxylate compounds as metalloprotease and TNF inhibitors.
ZA979406B (en) Metalloproteinase inhibitors pharmaceutical compositions containing them and their use
GB9702085D0 (en) Matrix metalloproteinase inhibitors

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees